Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma

Cancer Discovery

Volumn 8, Issue 1, 2018, Pages 37-48

  Pectasides, Eirini ^a,b   Stachler, Matthew D ^a,c   Derks, Sarah ^a,d   Liu, Yang ^a,e   Maron, Steven ^f   Islam, Mirazul ^a,e   Alpert, Lindsay ^f   Kwak, Heewon ^f   Kindler, Hedy ^f   Polite, Blase ^f   Sharma, Manish R ^f   Allen, Kenisha ^f   O’Day, Emily ^f   Lomnicki, Samantha ^f   Maranto, Melissa ^f   Kanteti, Rajani ^f   Fitzpatrick, Carrie ^f   Weber, Christopher ^f   Setia, Namrata ^f   Xiao, Shu Yuan ^f   Hart, John ^f   Nagy, Rebecca J ^g   Kim, Kyoung Mee ^h   Choi, Min Gew ^h   Min, Byung Hoon ^h   Nason, Katie S ⁱ   O’Keefe, Lea ⁱ   Watanabe, Masayuki ^j   Baba, Hideo ^k   Lanman, Rick ^g   Agoston, Agoston T ^c   Oh, David J ^l   Dunford, Andrew ^e   Thorner, Aaron R ^a   Ducar, Matthew D ^a   Wollison, Bruce M ^a   Coleman, Haley A ^a   Ji, Yuan ^f   Posner, Mitchell C ^f   Roggin, Kevin ^f   Turaga, Kiran ^f   Chang, Paul ^f   Hogarth, Kyle ^f   Siddiqui, Uzma D ^f   Gelrud, Andres ^f   Ha, Gavin ^e   Freeman, Samuel S ^e   Rhoades, Justin ^e   Reed, Sarah ^e   Gydush, Greg ^e   Rotem, Denisse ^e   Davison, Jon ⁱ   Imamura, Yu ^j,k   Adalsteinsson, Viktor ^e   Lee, Jeeyun ^m   Bass, Adam J ^a,e   Catenacci, Daniel V ^f   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g Guardant Health   (United States)

^h Sungkyunkwan University School of Medicine   (South Korea)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^j CANCER INSTITUTE HOSPITAL   (Japan)

^k KUMAMOTO UNIVERSITY   (Japan)

^l UNIVERSITY OF NEW ENGLAND   (United States)

^m Samsung Medical Center   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TRASTUZUMAB;

ARTICLE; CLINICAL ARTICLE; FGFR2 GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; STOMACH ADENOCARCINOMA; TUMOR BIOPSY; WHOLE EXOME SEQUENCING; ADENOCARCINOMA; COHORT ANALYSIS; ESOPHAGUS TUMOR; GENETICS; GENOMICS; PATHOLOGY; PROCEDURES; STOMACH TUMOR;

ADENOCARCINOMA; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; GENOMICS; HUMANS; PRECISION MEDICINE; STOMACH NEOPLASMS; WHOLE EXOME SEQUENCING;

EID: 85042565998     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-0395     Document Type: Article

References (54)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014;136: E359–86.
2. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;CD004064.
3. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–16
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–97.
6. Hecht JR, Bang Y-J, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-Positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC- A randomized phase III trial. J Clin Oncol 2016;34: 443–51.
7. Shah MA, Bang Y-J, Lordick F, Tabernero J, Chen M, Hack SP, et al. METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). ASCO Meeting Abstracts 2015;33:4012.
8. Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017 Sep 25. pii: S1470-2045(17)30566–1.
9. Bang Y-J, Van Cutsem E, Mansoor W, Petty RD, Chao Y, Cunningham D, et al. A randomized, open-label phase II study of AZD4547 (AZD) versus paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with fibroblast growth factor receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. ASCO Meeting Abstracts 2015;33:4014.
10. Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:490–9.
11. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AFC, Frances A, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:481–9.
12. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011;29:2972–7.
13. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30: 2522–9.
14. Boursault L, Haddad V, Vergier B, Cappellen D, Verdon S, Bellocq J-P, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohisto-chemical and molecular testing. PLoS ONE 2013;8:e70826.
15. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012;30:2956–62.
16. Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014;15:454.
17. Mao C, Wu X-Y, Yang Z-Y, Threapleton DE, Yuan J-Q, Yu Y-Y, et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep 2015;5:8065.
18. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13: 1036–43.
19. Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9:R31.
20. Hoefnagel LDC, van der Groep P, van de Vijver MJ, Boers JE, Wesseling P, Wesseling J, et al. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Ann Oncol 2013;24:3017–23.
21. Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest 2014;124:5145–58.
22. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202–9.
23. Ross-Innes CS, Becq J, Warren A, Cheetham RK, Northen H, O’Donovan M, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma. Nat Genet 2015;47:1038–46.
24. Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki JR, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol 2015;15:7.
25. Ye P, Zhang M, Fan S, Zhang T, Fu H, Su X, et al. Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis. PLoS ONE 2015;10:e0143207.
26. Silva ANS, Coffa J, Menon V, Hewitt LC, Das K, Miyagi Y, et al. Frequent coamplification of receptor tyrosine kinase and downstream signaling genes in japanese primary gastric cancer and conversion in matched lymph node metastasis. Ann Surg 2016; Published Ahead of Print:1.
27. Ahn S, Ahn S, Van Vrancken M, Lee M, Ha SY, Lee H, et al. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget 2015;6:38372–80.
28. Personeni N, Baretti M, Bozzarelli S, Spaggiari P, Rubino L, Tronconi MC, et al. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer 2017;20:428–37.
29. Park SR, Park YS, Ryu M-H, Ryoo B-Y, Woo CG, Jung H-Y, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer 2016;53: 42–50.
30. Saito T, Nakanishi H, Mochizuki Y, Ito S, Ito Y, Misawa K, et al. Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. Gastric Cancer 2015;18:711–9.
31. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011;104:1372–6.
32. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35:446–64.
33. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): final analysis of a Phase III study (JACOB). Ann Oncol 2017;28(Suppl 5):v209–68.
34. Murugaesu N, Wilson GA, Birkbak NJ, Watkins TBK, McGranahan N, Kumar S, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov 2015;5:821–31.
35. Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Godfrey JT, Clark JW, et al. Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discov 2015;5:1271–81.
36. Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov 2016;6:838–51.
37. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol 2015:2695–704.
38. Park J-L, Kim HJ, Choi BY, Lee H-C, Jang H-R, Song KS, et al. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett 2012;3:921–6.
39. Zhai R, Zhao Y, Su L, Cassidy L, Liu G, Christiani DC. Genome-wide DNA Methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and barrett esophagus. Neoplasia 2012;14:29–33.
40. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698–705.
41. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012; 4:162ra154–4.
42. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 2016;34:3375–82.
43. Fisher S, Barry A, Abreu J, Minie B, Nolan J, Delorey TM, et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol 2011;12:R1.
44. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685–9.
45. Cibulskis K, McKenna A, Fennell T, Banks E, DePristo M, Getz G. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 2011;27:2601–2.
46. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007; 23:657–63.
47. Olshen AB, Bengtsson H, Neuvial P, Spellman PT, Olshen RA, Seshan VE. Parent-specific copy number in paired tumor–normal studies using circular binary segmentation. Bioinformatics 2011;27:2038–46.
48. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014;25:91–101.
49. Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, et al. Paired exome analysis of Barrett’s esophagus and adenocarcinoma. Nat Genet 2015;47:1047–55.
50. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213–9.
51. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010;26:2069–70.
52. Abo RP, Ducar M, Garcia EP, Thorner AR, Rojas-Rudilla V, Lin L, et al. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res 2015; 43: e19–9.
53. Catenacci DVT. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 2015;9:967–96.
54. Catenacci DVT. Expansion platform type II: testing a treatment strategy. Lancet Oncol 2015;16:1276–8.